Leadership team

LGC’s board and executive management teams have an extensive understanding of the scientific marketplaces we serve. They are committed to supporting and creating opportunities for our employees worldwide, delivering high quality performance and services for our customers.

Board of directors

Tim Robinson - Chief Executive Officer

Tim Robinson - Chief Executive Officer

Tim joined LGC in 2013 as Chief Executive.

Tim has followed an international career in the technology and services sectors, spanning Engineering, Marketing and Corporate Leadership. Following a decade with IBM in Asia and Europe where he finished as a Director of IBM UK, Tim held senior executive positions in Silicon Graphics (SGI) and Thales, prior to being CEO for Xafinity, the privatised Office of the Paymaster General, and subsequently to Talaris (ex De La Rue).
 
Tim is a Non-Executive Director of the UK Government Department for International Development. He has also been a Non-Executive Board Member of UK Trade & Investment, a Member of the Association of Oxfam, serving on their Audit Committee, and a Non-Executive Director of Camelot Group.

Simon Parsons - Chief Financial Officer

Simon Parsons - Chief Financial Officer

Simon was appointed Chief Financial Officer of LGC on 4 October 2010. He joined LGC after working as CFO in two private equity investments owned by Apax Partners and Balderton Capital. Prior to that, Simon held a number of General Manager and Finance Director positions in the UK and Italy with Celesio AG, a leading European wholesale and retail pharmaceuticals business. He qualified with Ernst & Young in 1993 where he worked in the UK and US practices.

Dr Derek Craston - Chief Scientific Officer

Dr Derek Craston - Chief Scientific Officer

Derek Craston joined the LGC Board on 1 February 2012 as LGC's Chief Scientific Officer.  He continues with his existing role leading LGC's Health Science & Innovation division.

Derek's responsibilities as CSO include leading the scientific effort of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.

Euan O’Sullivan - Managing Director, LGC Standards

Euan O’Sullivan - Managing Director, LGC Standards

Having initially joined LGC as a Non-Executive Director in late 2007, Euan O’Sullivan assumed an executive role as Corporate Development Director in July 2010. In this role, Euan was responsible for the Group’s corporate development activities, including mergers, acquisitions, disposals and strategy development. He assumed his current role as Managing Director of the Standards division in July 2012.

Euan joined LGC from UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to LGC, Euan worked as a consultant in Accenture’s business strategy practice and within the M&A division of Close Brothers Corporate Finance. Euan is a graduate of University College, Oxford.

Brian Kim - President and Managing Director, LGC Genomics

Brian Kim - President and Managing Director, LGC Genomics

Brian Kim is Managing Director of the Genomics division. Brian has a wealth of experience in the genomics and broader life science market, having run large, complex global businesses for a number of major companies. Brian joined LGC from PerkinElmer, where he led the Life Sciences and Tools division, managing a global portfolio of various technologies and products ranging from instruments, reagents, service and software.

Brian holds a Master of Business Administration from Tuck School of Business at Dartmouth and a BS in Economics from the University of Pennsylvania.

Edouard Pillot - Non-Executive Director

Edouard Pillot - Non-Executive Director

Edouard joined the Board in March 2017, having joined KKR in 2006. Edouard is part of KKR’s Private Equity team, where he heads Business Services. Since joining KKR, Edouard has been involved in the investments in A-Gas, Travelopia, Välinge, SMCP and KION as well as the portfolio management of the investments in LGC, Maxeda and Northgate Information Solutions. Prior to joining KKR, he was with CIBC World Markets’ European leveraged finance group, and the diversified industrials investment banking department of J.P. Morgan in London and Paris. Edouard holds an MSc from the Ecole Superieure des Sciences Economiques et Commerciales (ESSEC).

Mark Danzey - Non-Executive Director

Mark Danzey - Non-Executive Director

Mark joined the Board in March 2016. Mark joined KKR Capital Markets (KCM) in 2009. Since joining KCM, Mark has worked on a variety of debt and equity financings for KKR portfolio companies and third party clients. Prior to joining KCM, Mark was a Vice President on J.P. Morgan’s leveraged finance capital markets desk and previously also worked in J.P. Morgan’s leveraged finance origination team. Mark spent the first year of his career at Deutsche Bank.

Dr Nicolas Roelofs - Non-Executive Director

Dr Nicolas Roelofs - Non-Executive Director

Nicolas joined the Board in April 2016. Prior to joining the Group, Nicolas served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group from 2009 to 2013. He also served as the Vice President and General Manager of the Life Sciences division from 2006 to 2009.

Prior to joining Agilent Technologies Inc., Nicolas was with Bio-Rad Laboratories, Inc. from 2005 to 2006 and served as the Life Science Group’s Group Operations Officer heading five business divisions spanning life science and food science. His time at Stratagene Corporation from 2001 to 2005 saw him serve as Senior Vice President of marketing, sales and business development for the first two years and as Chief Operating Officer for the last two years.

Professionally, Nicolas is a Global 50 Member and also a part of the Malaysian Biotechnology International Advisory Panel. He has also served on the Advisory Board of Chemical & Engineering News for the American Chemical Society Magazine. Nicolas completed his M.S. in Organic Chemistry from Iowa State University and has a PhD in Organic Chemistry from the University of Nevada, Reno.

Kugan Sathiyanandarajah - Non-Executive Director

Kugan Sathiyanandarajah - Non-Executive Director

Kugan joined the Board in March 2016, whilst at KKR. Kugan joined KKR in 2010 as co-head of European Healthcare and was involved with the investments in Alliance Boots and Northgate. Prior to joining KKR, Kugan was with Goldman Sachs, where he was a member of the UK mergers & acquisitions team. Kugan holds an M.A. (First Class Hons) in Physical Natural Sciences, specialising in theoretical chemistry, from the University of Cambridge.

 

Executive leadership team

Tim Robinson - Chief Executive Officer

Tim Robinson - Chief Executive Officer

Tim joined LGC in 2013 as Chief Executive.

Tim has followed an international career in the technology and services sectors, spanning Engineering, Marketing and Corporate Leadership. Following a decade with IBM in Asia and Europe where he finished as a Director of IBM UK, Tim held senior executive positions in Silicon Graphics (SGI) and Thales, prior to being CEO for Xafinity, the privatised Office of the Paymaster General, and subsequently to Talaris (ex De La Rue).
 
Tim is a Non-Executive Director of the UK Government Department for International Development. He has also been a Non-Executive Board Member of UK Trade & Investment, a Member of the Association of Oxfam, serving on their Audit Committee, and a Non-Executive Director of Camelot Group.

Simon Parsons - Chief Financial Officer

Simon Parsons - Chief Financial Officer

Simon was appointed Chief Financial Officer of LGC on 4 October 2010. He joined LGC after working as CFO in two private equity investments owned by Apax Partners and Balderton Capital. Prior to that, Simon held a number of General Manager and Finance Director positions in the UK and Italy with Celesio AG, a leading European wholesale and retail pharmaceuticals business. He qualified with Ernst & Young in 1993 where he worked in the UK and US practices.

Dr Derek Craston - Chief Scientific Officer

Dr Derek Craston - Chief Scientific Officer

Derek Craston joined the LGC Board on 1 February 2012 as LGC's Chief Scientific Officer.  He continues with his existing role leading LGC's Health Science & Innovation division.

Derek's responsibilities as CSO include leading the scientific effort of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.

Euan O’Sullivan - Managing Director, LGC Standards

Euan O’Sullivan - Managing Director, LGC Standards

Having initially joined LGC as a Non-Executive Director in late 2007, Euan O’Sullivan assumed an executive role as Corporate Development Director in July 2010. In this role, Euan was responsible for the Group’s corporate development activities, including mergers, acquisitions, disposals and strategy development. He assumed his current role as Managing Director of the Standards division in July 2012.

Euan joined LGC from UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to LGC, Euan worked as a consultant in Accenture’s business strategy practice and within the M&A division of Close Brothers Corporate Finance. Euan is a graduate of University College, Oxford.

Brian Kim - President and Managing Director, LGC Genomics

Brian Kim - President and Managing Director, LGC Genomics

Brian Kim is Managing Director of the Genomics division. Brian has a wealth of experience in the genomics and broader life science market, having run large, complex global businesses for a number of major companies. Brian joined LGC from PerkinElmer, where he led the Life Sciences and Tools division, managing a global portfolio of various technologies and products ranging from instruments, reagents, service and software.

Brian holds a Master of Business Administration from Tuck School of Business at Dartmouth and a BS in Economics from the University of Pennsylvania.

Dr Frances Crummay - Chief Information Officer

Dr Frances Crummay - Chief Information Officer

Frances Crummay joined LGC in September 2011 and was promoted to Chief Information Officer (CIO) in January 2014. Her responsibilities cover the full range of global IT operations including IT strategy, policy, security and disaster recovery. She is responsible for ensuring the effective delivery of IT services and digital communications across the operational and scientific communities with the strategic intention of putting innovation and technology at the heart of LGC’s business.
 
Frances has a PhD and started her career at the Met Office. She has run complex IT systems and services for a variety of companies including Zurich Insurance, Businesslink.gov.uk and DSTL (Defence, Science and Technology Laboratory).

Michael Dubois - Corporate Development Director

Michael Dubois - Corporate Development Director

Michael joined LGC in 2011 and leads the Group’s corporate development activities, including mergers, acquisitions, disposals and strategy development. Prior to joining LGC, Michael was at Close Brothers Corporate Finance where he was a Managing Director in the firm’s M&A team. Michael holds an M.A. (First Class Hons) in Natural Sciences, specialising in organic chemistry, from the University of Cambridge

Dr David Griffiths - Managing Director, Pharma & Health Solutions

Dr David Griffiths - Managing Director, Pharma & Health Solutions

David Griffiths currently heads up our Drug Development Solutions (DDS) business.  With operational sites in the UK, Germany and the US, DDS provides bioanalytical, CMC analytical and therapeutic oligonucleotide discovery, development and manufacturing solutions for biotech and pharmaceutical clients around the world.  In addition, David leads strategy development and the commercial team for Health Science & Innovation.

David was Managing Director of LGC’s Laboratory & Managed Services Division from September 2014 through to July 2017 having joined LGC in 2013 when LGC acquired the leading bioanalytical business from Quotient Bioresearch. Prior to LGC, David held a variety of operational, commercial and senior leadership roles in pharma, biotech and CROs.

Neetu Ogle - General Counsel and Company Secretary

Neetu Ogle - General Counsel and Company Secretary

Neetu joined LGC in 2016, as General Counsel and Company Secretary. She has overall responsibility for the LGC Group’s legal, company secretarial and IP management functions. Neetu is an experienced corporate and commercial lawyer with a first-class legal background gained at leading national and international law firms, Wragge & Co and Allen & Overy. Her private practice experience has been consolidated by ten years at FTSE 350 companies, QinetiQ Group plc and, more recently, Inmarsat plc. 

Jon Yeung - Chief Operating Officer, LGC Standards

Jon Yeung - Chief Operating Officer, LGC Standards

Jon was appointed Chief Operating Officer at LGC Standards in 2017.

Previously, Jon was Group Finance Director and then Managing Director of LGC Forensics, having joined LGC as Group Financial Controller in March 2011.

Before joining LGC, Jon worked at PwC in a variety of commercial and operational roles in the UK and US in the life science, pharma and broader industrial sectors. Jon is a qualified chartered accountant and member of the ICAEW, holding an MA (Oxon) from Wadham College, Oxford University.


Science advisory board

Dr Laurie Locascio - Chair, University of Maryland

Dr Laurie Locascio - Chair, University of Maryland

Laurie E. Locascio, Ph.D., is the Vice President for Research at the University of Maryland.

Previously Laurie worked at the National Institute of Standards and Technology (NIST) in Gaithersburg, MD, rising from a research biomedical engineer to senior leadership positions, including most recently, Acting Principal Deputy Director and Associate Director for Laboratory Programs, providing leadership and operational guidance for NIST's seven scientific and mission-focused laboratories.

Laurie's most recent honors and awards include the 2017 American Chemical Society Earle B. Barnes Award for Leadership in Chemical Research Management, and the 2017 Washington Academy of Sciences Special Award in Scientific Leadership.  She has published 115 scientific papers and holds 11 patents in the fields of bioengineering and analytical chemistry. Laurie is a Fellow of the American Chemical Society (ACS) and the American Institute for Medical and Biological Engineering (AIMBE).

Dr Ron Cook - Advisor

Dr Ron Cook - Advisor

Dr Ron Cook, is an entrepreneurial scientist focused on the development, application and commercialisation of synthetic nucleic acids. 

Ron has a Chemistry degree from UC Berkeley, a PhD from the University of Washington, Seattle, Department of Chemistry, and postdoctorate from the University of California, San Francisco, Department of Microbiology and Immunology.

Ron founded Biosearch, Inc in 1977 to supply synthetic peptides and protein bioconjugates to the research community. In 1980, the production of synthetic nucleic acids propulsed the company to become a leading innovator in oligonucleotide chemistry and a leader in the supply and technology development for synthetic DNA.  In 1982, the company developed the first commercially viable oligo synthesizer (SAM I), which enabled the invention of PCR in 1983. Over the next 30 years, under Ron’s leadership, Biosearch or its descendent entities, participated in the development of many oligo-driven technologies, including PCR, therapeutic antisense oligos, synthetic gene manufacture, sequencing of the human genome, si-RNA, and recently, fluorescent probes for genomic analysis and qPCR.   

Ron has published over 30 scientific papers and issued more than 25 patents. Today, Ron is chairman of a number of organisations in the US, Denmark and Germany. He is also co-founder and chairman of Optical Biosystems.

Dr Gene Yeo - University of California, San Diego

Dr Gene Yeo - University of California, San Diego

Dr. Gene Yeo is an expert in the areas of RNA biology and therapeutics, computational biology, genomics and neurological diseases.

Gene is a Professor of Cellular and Molecular Medicine at the University of California, San Diego (UCSD). He has a BSc in Chemical Engineering and a BA in Economics from the University of Illinois, Urbana-Champaign, a Ph.D. in Computational Neuroscience from Massachusetts Institute of Technology and an MBA from the UCSD Rady School of Management.

Gene’s research interest is in understanding and manipulating RNA processing in development and disease using induced pluripotent stem cell and murine models. His lab demonstrated in vivo RNA targeting with CRISPR/Cas proteins with proof of concept in repeat expansion disorders. Gene’s lab developed enhanced CLIP for the purposes of large-scale mapping of protein-RNA interactions. His lab is an active participant in RNA genomics technology and therapeutics development.

Gene is on the Editorial Boards of the journals Cell Reports and Cell Research. He is a recipient of Alfred P Sloan Fellowship in recognition of his work in computational molecular biology (2011) and the inaugural Early Career Award from the International RNA Society (2017).

Gene is a co-founder of several biotech companies including Locana, Eclipse Bioinnovations, Enzerna and Proteona. He serves or had served on the scientific advisory boards of the Allen Institute of Immunology, Locana, Eclipse Bioinnovations, Proteona, Aquinnah, LGC, Nugen and Ribometrix.

Prof. Duncan Graham - University of Strathclyde

Prof. Duncan Graham - University of Strathclyde

Duncan Graham is the Research Professor of Chemistry and Head of Department for Pure and Applied Chemistry at the University of Strathclyde in Glasgow. 

Duncan obtained his BSc Honours and PhD in Chemistry from the University of Edinburgh before joining the University of Strathclyde in 1996. He is Editor in Chief of the RSC journal Analyst and serves several editorial advisory boards including Chemical Society Reviews and Chemical Science.

Duncan is president of the analytical division of the Royal Society of Chemistry and chair of the analytical chemistry trust fund. He has published over 250 papers with 16 patents and has supervised over 60 PhD students and 35 postdoctoral researchers.

Duncan’s scientific interests are in using synthetic chemistry to produce sensors that respond to a specific biological species or events as measured by Raman spectroscopy or SERS.